These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 37507762)

  • 1. A GATA2-CDC6 axis modulates androgen receptor blockade-induced senescence in prostate cancer.
    Mourkioti I; Polyzou A; Veroutis D; Theocharous G; Lagopati N; Gentile E; Stravokefalou V; Thanos DF; Havaki S; Kletsas D; Panaretakis T; Logothetis CJ; Stellas D; Petty R; Blandino G; Papaspyropoulos A; Gorgoulis VG
    J Exp Clin Cancer Res; 2023 Jul; 42(1):187. PubMed ID: 37507762
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel androgen receptor-binding element modulates Cdc6 transcription in prostate cancer cells during cell-cycle progression.
    Jin F; Fondell JD
    Nucleic Acids Res; 2009 Aug; 37(14):4826-38. PubMed ID: 19520769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting DNA Damage Response in Prostate Cancer by Inhibiting Androgen Receptor-CDC6-ATR-Chk1 Signaling.
    Karanika S; Karantanos T; Li L; Wang J; Park S; Yang G; Zuo X; Song JH; Maity SN; Manyam GC; Broom B; Aparicio AM; Gallick GE; Troncoso P; Corn PG; Navone N; Zhang W; Li S; Thompson TC
    Cell Rep; 2017 Feb; 18(8):1970-1981. PubMed ID: 28228262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interleukin-23 Represses the Level of Cell Senescence Induced by the Androgen Receptor Antagonists Enzalutamide and Darolutamide in Castration-Resistant Prostate Cancer Cells.
    Gupta S; Pungsrinont T; Ženata O; Neubert L; Vrzal R; Baniahmad A
    Horm Cancer; 2020 Aug; 11(3-4):182-190. PubMed ID: 32562083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Androgen Receptor Regulation of Local Growth Hormone in Prostate Cancer Cells.
    Recouvreux MV; Wu JB; Gao AC; Zonis S; Chesnokova V; Bhowmick N; Chung LW; Melmed S
    Endocrinology; 2017 Jul; 158(7):2255-2268. PubMed ID: 28444169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natural product myricetin is a pan-KDM4 inhibitor which with poly lactic-co-glycolic acid formulation effectively targets castration-resistant prostate cancer.
    Liu JS; Fang WK; Yang SM; Wu MC; Chen TJ; Chen CM; Lin TY; Liu KL; Wu CM; Chen YC; Chuu CP; Wang LY; Hsieh HP; Kung HJ; Wang WC
    J Biomed Sci; 2022 May; 29(1):29. PubMed ID: 35534851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. UHRF1 promotes androgen receptor-regulated CDC6 transcription and anti-androgen receptor drug resistance in prostate cancer through KDM4C-Mediated chromatin modifications.
    Gao Y; Liu Y; Liu Y; Peng Y; Yuan B; Fu Y; Qi X; Zhu Q; Cao T; Zhang S; Yin L; Li X
    Cancer Lett; 2021 Nov; 520():172-183. PubMed ID: 34265399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IU1 and enzalutamide combination yields synergistic effects on castration-resistant prostate cancer.
    Zhang Y; Liao Y; Luo M; Ye Y; Xu Z; Hou W; Liu R; Zhai Q; Lv S; Wei Q
    Prostate; 2023 Nov; 83(15):1446-1457. PubMed ID: 37545197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enzalutamide, an androgen receptor signaling inhibitor, induces tumor regression in a mouse model of castration-resistant prostate cancer.
    Guerrero J; Alfaro IE; Gómez F; Protter AA; Bernales S
    Prostate; 2013 Sep; 73(12):1291-305. PubMed ID: 23765603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SRF inhibitors reduce prostate cancer cell proliferation through cell cycle arrest in an isogenic model of castrate-resistant prostate cancer.
    Azam H; Maher S; Clarke S; Gallagher WM; Prencipe M
    Cell Cycle; 2023; 22(14-16):1759-1776. PubMed ID: 37377210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Attenuating Adaptive VEGF-A and IL8 Signaling Restores Durable Tumor Control in AR Antagonist-Treated Prostate Cancers.
    Maxwell PJ; McKechnie M; Armstrong CW; Manley JM; Ong CW; Worthington J; Mills IG; Longley DB; Quigley JP; Zoubeidi A; de Bono JS; Deryugina E; LaBonte MJ; Waugh DJJ
    Mol Cancer Res; 2022 Jun; 20(6):841-853. PubMed ID: 35302608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Restoration of the cellular secretory milieu overrides androgen dependence of in vivo generated castration resistant prostate cancer cells overexpressing the androgen receptor.
    Patki M; Huang Y; Ratnam M
    Biochem Biophys Res Commun; 2016 Jul; 476(2):69-74. PubMed ID: 27179779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LINC00675 activates androgen receptor axis signaling pathway to promote castration-resistant prostate cancer progression.
    Yao M; Shi X; Li Y; Xiao Y; Butler W; Huang Y; Du L; Wu T; Bian X; Shi G; Ye D; Fu G; Wang J; Ren S
    Cell Death Dis; 2020 Aug; 11(8):638. PubMed ID: 32801300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PMA induces androgen receptor downregulation and cellular apoptosis in prostate cancer cells.
    Itsumi M; Shiota M; Yokomizo A; Takeuchi A; Kashiwagi E; Dejima T; Inokuchi J; Tatsugami K; Uchiumi T; Naito S
    J Mol Endocrinol; 2014 Aug; 53(1):31-41. PubMed ID: 24780839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The androgen receptor-lncRNASAT1-AKT-p15 axis mediates androgen-induced cellular senescence in prostate cancer cells.
    Mirzakhani K; Kallenbach J; Rasa SMM; Ribaudo F; Ungelenk M; Ehsani M; Gong W; Gassler N; Leeder M; Grimm MO; Neri F; Baniahmad A
    Oncogene; 2022 Feb; 41(7):943-959. PubMed ID: 34667276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the androgen receptor signaling pathway in advanced prostate cancer.
    Chung C; Abboud K
    Am J Health Syst Pharm; 2022 Jul; 79(15):1224-1235. PubMed ID: 35390118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Androgen receptor-dependent and -independent mechanisms driving prostate cancer progression: Opportunities for therapeutic targeting from multiple angles.
    Hoang DT; Iczkowski KA; Kilari D; See W; Nevalainen MT
    Oncotarget; 2017 Jan; 8(2):3724-3745. PubMed ID: 27741508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular determinants for enzalutamide-induced transcription in prostate cancer.
    Yuan F; Hankey W; Wu D; Wang H; Somarelli J; Armstrong AJ; Huang J; Chen Z; Wang Q
    Nucleic Acids Res; 2019 Nov; 47(19):10104-10114. PubMed ID: 31501863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel androgen receptor antagonist JJ-450 inhibits enzalutamide-resistant mutant AR
    Wu Z; Wang K; Yang Z; Pascal LE; Nelson JB; Takubo K; Wipf P; Wang Z
    Prostate; 2020 Mar; 80(4):319-328. PubMed ID: 31868960
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined N-terminal androgen receptor and autophagy inhibition increases the antitumor effect in enzalutamide sensitive and enzalutamide resistant prostate cancer cells.
    Kranzbühler B; Salemi S; Mortezavi A; Sulser T; Eberli D
    Prostate; 2019 Feb; 79(2):206-214. PubMed ID: 30345525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.